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Abstract Rofecoxib (Vioxx© made by Merck Sharp &
Dohme, the USA) is a non-steroidal anti-inflammatory drug
which belongs to the group of selective inhibitors of
cyclooxygenasis-2, i.e., coxibs. Rofecoxib was first registered
in the USA, in May 1999. Since thenthedrug was received by
millions of patients. Drugs of this group were expected to
exhibit increased therapeutic action. Additionally, there were
expectations concerning possibilities of their application, at
least asauxiliary drugs, in neoplastic therpydue to intensifying
of apoptosis. In connection with the withdrawal of Vioxx©
(rofecoxib) from pharmaceutical market, attempts were made
to conduct electron-microscopic evaluation of cortical part of
the adrenal gland in preparations obtained from animals under
influence of the drug. Every morning animals from the
experimental group (15 rats) received rofecoxib (suspension
in physiological saline)—non-steroidal anti-inflammatory
drug (Vioxx©, Merck Sharp and Dohme, the USA), through
an intragastric tube in the dose of 1.25 mg during 8 weeks. In
the evaluated material, there was found a greater number of
secretory vacuoles and large, containing cholesterol and other
lipids as well as generated glucocorticoids, lipid drops in
cytoplasmcontainingprominentendoplasmicreticulum.There
were also found cells with cytoplasm of smaller density—
especially in apical and basal parts of cells. Mitochondria
occasionally demonstrated features of delicate swelling. The
observed changes, which occurred on cellular level with
application of large doses of the drug, result from mobilization
of adaptation mechanisms of the organism.
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Abbreviations
ACTH Adrenocorticotropic hormone
ALAT Alanine amino transferase
APROV Adenomatous polyp prevention on Vioxx
ASPAT Aspargin amino transferase
COX Cyclooxygenase
COX-1 Cyclooxygenase-1
COX-2 Cyclooxygenase-2
GRE Glucocorticoid response elements
IL Interleukin
IL-1β Interleukin-1β
LPS Lipopolysaccharide
NFκB Nuclear factor κB
NF-IL-6 Nuclear factor IL-6
NP Sodium nitroprusside
NSAID Non-steroidal anti-inflammatory drugs
PGs Prostaglandins
PGE2 Prostaglandin E2
SER Smooth endoplasmic reticulum
TNFα Tumor necrosis factor α
TLR-2 Toll-like receptor 2
TLR-4 Toll-like receptor 4
VIGOR Vioxx Gastrointestinal Outcomes Research
Introduction
Non-steroidal anti-inflammatory drugs are a group of com-
monly used medications which show anti-inflammatory,
analgesic, and antipyretic action (Huang 2000; Crofford
2001; Courtney and Doherty 2002; Spiegel et al. 2003;
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At the beginning of the 1990s the discovery of cyclo-
oxygenase isoforms enabled a better understanding of
inflammation pathomechanism, which led to the creation
of a new class of drugs, namely coxibs. They display anti-
inflammatory action comparable to the classic non-steroidal
anti-inflammatory drugs, with minimal adverse effects
(Vane et al. 1990; Huang 2000; Luo et al. 2005).
Until the beginning of the 1990s only one enzyme of
cyclooxygenase activity had been believed to exist. At that
time there was observed a considerable increase in cyclo-
oxygenase protein concentration in experimental condi-
tions. In 1990 (Masferrer et al. 1990), discovered an
increaseincyclooxygenaseproteinconcentrationinperitoneal
macrophages of mice, in which an inflammatory condition
was induced by intravenous administration of bacterial
lipopolysaccharide. That increase was inhibited by cortico-
steroids. In the same year, Fu et al. (1990)p r o v e dc y c l o -
oxygenase protein induction in human monocytes. In
1989, while studying neoplastic transformation of domestic
chicken embryo fibroblasts infected with Rous sarcoma,
Simmons et al. (1989) discovered an increase in the
concentration of several, different sequences of mRNA.
Further investigations (Bakhle 1999)r e v e a l e dt h a to n eo f
those sequences codes for an enzyme of cyclooxygenase
activity.
The studies of Needleman and Manning (1999) and
Simmons et al. (2004) contributed to the discovery of the
existence of two isoforms of cyclooxygenase cyclooxyge-
nase (COX)-1 and COX-2. The next years brought along
synthesizing and introducing of selective inhibitors COX-2
into treatment. Those drugs show effective anti-inflammatory
action and incomparably smaller adverse effects in relation to
non-selective drugs (Lipsky et al. 2000).
In normal conditions, COX-2 expression is practically
undetectable in most tissues, and it increases several times
after stimulation. In vitro an increase in gene expression for
COX-2 was discovered, e.g., after stimulation of cells with:
cytokines (IL-1β, TNF-α), mitogens, phorbol esters, serum,
and tetracycline (Connel et al. 1994; Ichitani et al. 2001).
The gene activity is inhibited by corticosteroids Il-4 and
Il-10 (Tominaga et al. 1991; Weber et al. 1997). Apart from
reducing of gene expression, corticosteroids decrease the
stability of mRNA for COX-2. In vivo an increase in
enzyme expression and level of COX-2 protein was
discovered in bioptic material from inflamed tissues of air
passages, skin, alimentary tract and many other organs.
Both isoforms also differ in intracellular location. The
activity of COX-1 is mainly located in the vicinity of
endoplasmic reticulum, whereas COX-2 mainly occurs in
the area of external nuclear membrane (Gierse et al. 1996;
Whittle 2000).
Apart from its direct participation in the process of
prostaglandin synthesis, COX-1 also affects the production
of gastric juice, and thus was responsible for chronic
inflammation of stomach mucous membranes in longer
administration of drugs blocking that enzyme (Langman et
al.1999; Warner and Mitchell 2004). COX-2 is only engaged
in the process of prostaglandin synthesis (Price-Forbes et al.
2005). COX-2 seemed to be an ideal target for non-steroidal
anti-inflammatory drugs (NSAID). This beneficially resulted
in the introduction of COX-2 selective inhibitors into medical
practice in the late 1990s. Rofecoxib (Vioxx), Celecoxib
(Celebrex), Valdecoxib (Bextra), Etericoxib (Arcoxia)
(Fig. 1) soon achieved a strong position in the pharmaceu-
tical market (Kawamori et al. 1998; Malmstrom et al. 1999;
Steinbach et al. 2000; Dannhardt and Kiefer 2001; Zarraga
and Schwarz 2007). The appearance of those drugs, which
undoubtedly gave new and promising prospects in medical
care, was enthusiastically considered a breakthrough in the
therapy of pain and inflammatory processes (Mandell 1999).
Rofecoxib (marketed under the brand name of Vioxx), i.e.,
4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan, is non-
steroidal anti-inflammatory drug from the group of
diphenylfuran. It shows anti-inflammatory, analgesic, and
antipyretic actions (Ehrich et al. 1999). It was mainly used in
the treatment of acute and chronic phase of degenerative
joint disease, and also in osteoporosis as an analgesic agent.
It inhibits the activity of COX-2 approximately 800 times
more strongly than COX-1 activity, affecting the arrest of
synthesis of prostaglandins induced during inflammatory
process (Hellstrom 2007). Rofecoxib is administered in the
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Fig. 1 Structural formulas of selective inhibitors COX
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form of tablets or suspension. The drug is almost completely
absorbed (approximately 93%) from the alimentary track.
The maximum concentration in plasma occurs after approx-
imately 3 h and amounts to 0.305 mg/l in stationary
condition. When the drug is administered together with
food, its maximum concentration is after approximately
4–5 h, but the total amount of absorbed drug, its maximum
concentration or biological availability do not change (Scali
et al. 2003). However, simultaneous administration of drugs
neutralizing hydrochloric acid decreases its absorption.
Rofecoxib is metabolized in the liver by cytosol enzymes.
The main pathway of metabolism is reduction of the drug
to cis-dihydro-derivatives and trans-dihydro-derivatives of
rofecoxib, which do not show any reaction to cyclooxyge-
nase activity. Cytochrome P-450 plays only a small role in
rofecoxib metabolism. Through its action the drug is trans-
formed into hydroxylic derivative which is then combined
with glucuronic acid. In this way 9% of the drug is
metabolized, consequently inhibiting of cytochrome activity
has practically no effect on the drug kinetics (Scali et
al. 2003).
Apart from the side effects typical of NSAID, such as
alimentary track disorders (nausea, vomiting, abdominal
pains), impairment of liver functions (liver failure and
inflammation) may also occur. In the kidneys adverse
effects are connected with inhibiting of E2 (PGE2) and E2
(PGE2) prostaglandins synthesis by rofecoxib (Mohn et al.
2005). These compounds are responsible for regulating of
secretion and absorption of sodium and potassium ions.
Decrease in prostaglandins concentration due to the use of
Vioxx preparation contributes to the occurrence of numer-
ous kidney diseases such as renal failure, ischaemia and
inflammatory conditions (Fletcher et al. 2006). Disorders in
sodium-potassium balance on renal level have consequences
affecting the whole organism, and cause hyperkalemia,
retention of water in the organism and occurrence of oedema.
Rofecoxib also affects the occurrence of thrombotic-embolic
episodes. In patients using rofecoxib there was also observed
an increase in the activity of liver enzymes ALAT, ASPAT,
and decrease in hematocrit value, the number of erythro-
cytes, hemoglobin and leucocytes. However, the activity of
alkaline phosphatase, levels of urea and creatinine rise during
treatment with the drug (Hawkey 1999).
Vioxx was introduced into the pharmaceutical market in
1999, approved by Food and Drug Administration (FDA).
Even before the drug launch there had appeared first
information about its toxicity. Vioxx considerably reduced
the risk of bleeding and ulceration of the alimentary track.
This one-sided emphasizing of the lack of gastrological
toxicity while ignoring other unfavorable cases was the
cause of introducing of Vioxx into the market based on
VIGOR study. The assumption of that study (Bombardier et
al. 2000) was to prove the drug safety in the aspect of
complications in the alimentary track. At the same time the
study revealed that the drug increases the risk of myocardial
infarction five times. The justification that a myocardial
infarction which developed in the period of time shorter
than 18 months after the use of rofecoxib had not been
caused by the drug also proved to be faulty.
The study which turned out to decide about the future of
rofecoxib was APROV study (Głuszko 2004), which was to
evaluate rofecoxib effectiveness in the treatment of large
intestine polyps in patients with diagnosed adenomas of
large intestine. The study was interrupted immediately after
there had been detected an increased risk of thrombus,
cardiac infarction and cerebral stroke occurrence in the
group receiving rofecoxib.
In 2004, Merck Sharp & Dohme (MSD) company
withdrew Vioxx (rofecoxib) drug, which was then available
in 80 countries in the world and used in the treatment of
pain in the course of rheumatic diseases. The company’s
decision was affected by the results of clinical trials which
revealed an increased risk of cardiac-vascular incidents in
patients receiving that drug (Kim et al. 2004; Lenzer 2005;
Thomas 2006; Wadman 2007; Haag et al. 2008; Krumholz
et al. 2008; Roumie et al. 2008).
Materials and methods
The study was conducted on male white rats of Wistar
strain, with body mass of 300–350 g, which stayed in the
same conditions and received standard diet and drinking
water ad libitum during the experiment.
The control group consisted of animals (ten rats) which
did not receive any other substance except standard
granulated fodder and drinking water.
Every morning the animals from the experimental group
(15 rats) received rofecoxib (suspension in physiological
saline)—a non-steroidal anti-inflammatory drug (Vioxx©
preparation, Merck Sharp and Dohme, the USA), through
an intragastric tube in the dose of 1.25 mg during 8 weeks.
After finishing of the experiment cycle the rats were
decapitated and sections including the cortical part (zona
fasciculata) of the adrenal gland were obtained for
ultrastructural examination.
The sections of the cortical part of the adrenal glands
were fixed for 2 h in the solution of glutaraldehyde in
phosphate buffer with pH 7.2. The material was further
fixed in 1% solution of OsO4, dehydrated in a series of
alcohols with rising concentration and embedded in
Durcupan resin (ACM Fluka). The blocks were polymer-
ized at the temperature of 60°C, then cut by means of
ultramicrotom cutter made by Reichert company. Ultrathin
sections were contrasted using uranyl acetate and lead
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graphed using an electron microscope Tesla BS 500.
The study results were analyzed statistically. The values
of the analyzed measurable parameters were characterized
using mean value and standard deviation. Due to the
skewed distribution of the studied parameters evaluated
by means of the Shapiro–Wilk test or heterogeneity of
variances evaluated by the F-test, the Mann–Whitney U test
was used to analyze the differences between the studied
subgroups. There was assumed 5% inference error and the
differences were considered statistically significant when
p<0.05. The statistical analyses were conducted using
STATISTICA v. 8.0 (StatSoft, Polska).
Results
Electron microscopy
Control group
In the examined preparations obtained from the control
group animals the ultrastructural images of the adrenal
cortex zona fasciculata cells were normal (Fig. 3).
Large cell sizes and considerable abundance of organelles
were particularly noticeable. The cells were dominated by
round nuclei, the largest of the cell nuclei from all the adrenal
cortex zones. Electron-dense heterochromatin created irregu-
lar clusters, mainly situated near the nuclear envelope, where
nucleopores could be spotted. In the nucleus located in the
centralpartoflargepolygonal(cubic)cellstherewereelectron
dense 1 or 2 nucleoli of irregular shape.
The electron microscope showed a well-developed
smooth endoplasmic reticulum and the Golgi apparatus
located close to the nucleus, on the pericapillary side.
Mitochondria were more numerous than in the zona
glomerulosa cells, more oval in shape and contained,
almost exclusively, tubular and vesicular cristae. The
mitochondrial matrix was electron lucent. Apart from
typical cytoplasmic structures there occurred lysosomes
containing crystal structures. Lumina of numerous capillary
vessels were visible. On the side of the capillary the cell
wall contained microvilli, which sometimes perforated the
basement membrane of the glandular epithelium and
contacted the pericapillary space.
Experimental group
In the studied material from the experimental group of
animals there were visible all the cellular organelles: the
cell nucleus with 1 or 2 nucleoli, rough and smooth
endoplasmic reticula, secretory vacuoles and lipid drops,
the Golgi structures, mitochondria, lysosomes.
The zona fasciculata glandular cells were heterogenous,
some of them contained nuclei with dense chromatin, the
others, however, had nuclei with rare chromatin. The
proportions of euchromatin to heterochromatin occurrence
weresimilar tothe control groupimage.Therecouldbeseena
well-developedendoplasmic reticulum withsingleribosomes,
and also polyribosomes lying in groups, which had contact
with the external membranes of the endoplasmic reticulum.
The Golgi apparatus was less visible than in the control group
images. In its structure, the following elements could be
identified:cisternae(dictyosomes),flattenedinthecentralpart
and widened in the peripheral part, numerous vesicles, and
large vacuoles containing non-structural or granular material.
What is important, as a result of the conducted experiment, in
the cytoplasm with prominent endoplasmic reticulum there
was found (Fig. 2a, b) a greater number of secretory
vacuoles, a considerable increase in the number of lipid
drops containing cholesterol, other types of lipids and
generated glucocorticoids, as compared with the preparations
from the control group animals. There were also observed
Fig. 2 Control group. Cell of adrenal cortex zona fasciculata.
Magnification 10,000×. a, b Experimental group. Cell of adrenal
cortex zona fasciculata. In cytoplasm there are numerous secretory
vacuoles. Magnification 12,000×
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apical and basal parts of the cells.
In most cells the Golgi structures occurred individually
and in close vicinity of the nucleus. In a few images this
structure was dispersed in the form of numerous dictyo-
somes. The particular parts of the Golgi apparatus showed a
clear polarization of the complex. In this structure two
regions could be identified—the proximal one cis and the
distal one trans, in which there were large, formed vacuoles
containing amorphous or granular material. Most often
these were secretory granules or lysosomes. There were
observed modified forms of mitochondria, characteristic of
all the adrenal cortex cells, which neighboured on the
endoplasmic reticulum. The mitochondria, similarly to the
control group, had tubular or vesicular cristae, which
resembled a honeycomb in appearance. The mitochondria
matrix was electron lucent. These organelles occasionally
demonstrated features of delicate swelling.
Lysosomes containing electron-dense material had a
form of small structures with homogenous or granular
content. Apart from primary lysosomes these organelles
were also found in the form of large heterophagic vacuoles.
Statistics
Thestatisticalanalysisrevealedhighermeanvaluesofsecretory
vacuolesandlipiddropsnumbersinthezonafasciculatacellsof
the adrenal cortex in the experimental group of animals
compared with the control group (Table 1). Considerably more
lipid drops were observed in the adrenal cortex cells of the
animals which had received rofecoxib (Fig. 3). The analysis of
variance showed statistically significant differences between
the studied groups (p<0.0001).
Discussion
For many years there have been conducted studies aimed at
explaining of mutual relations of the hypothalamus-
hypophysis-adrenal gland axis (Bornstein and Chrousos
1999; Belenguer-Garcia et al. 2006; Neeck 2000). The
feedback mechanism is a type of regulation in which
the level of produced substance affects the rate of its
production.
Mutual functional relations within the hypothalamus-
hypophysis-peripheral endocrine glands axis and feedback
effects determine the synthesis and secretion of hormones
on different levels. Seeking cause-effect relations between
changes in morphological structure of endocrine glands
incurred by exogenous substances and functioning of the
axis acquires particular importance (Müller et al. 1999).
Defects in the functioning of the hypothalamus-hypophysis-
endocrine glands axis or dysfunctions in each of its elements
can cause metabolic disorders manifesting themselves
with occurrence of disease syndromes (Barraclough and
Haller 1970).
Adrenocorticotropic hormone is the most important of
the compounds stimulating the adrenal cortex to synthesize
and release glucocorticoids, for instance, under conditions
of stress.
The group of scientists (Mohn et al. 2005) managed to
evaluate the mechanism of adrenocorticotropic hormone
(ACTH) effects on the adrenal glands of male rats in vitro,
preserving the structure of the gland. It was proved that
both sodium nitroprusside (NP)—a donor of nitrogen oxide
(NO) and also ACTH stimulate the secretion of cortisol.
NO mediates in the acute response to ACTH, which is
Table 1 Mean values and standard deviations of secretory vacuoles and lipid drops numbers in the zona fasciculata cells of the adrenal cortex
Group Secretory vacuoles Lipid drops
Number
of analyzed
sections
Mean Standard
deviation
(SD)
Minimum Maximum Number
of analyzed
sections
Mean Standard
deviation
(SD)
Minimum Maximum
Control 30 3.900 0.971 3.000 7.00 30 5.400 1.316 2.00 8.00
Experimental 45 4.777 1.387 4.000 10.00 45 13.333 3.076 8.00 18.00
Variance analysis F=46.33; p<0.0001
Fig. 3 Mean values of vacuoles numbers in particular groups
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ester—NO synthesis inhibitor, as well as hemoglobin—NO
sweeper, block cortisol release in response to ACTH.
Cortisol secretion induced by ACTH or NP caused
emptying of the adrenal glands of the hormone in about
40%, as compared with the control adrenal glands. The
mechanism of cortisol sudden release is the following: NO
produced by NO synthesis activated by ACTH, activates
COX, under COX influence PGE2 is generated, and it
causes cortisol release from secretory follicles and other
organelles (Mohn et al. 2005).
Moreover, there was found a stimulating influence of
exogenous PGE2 (10
-9 mol/l) on the production of aldoste-
rone by isolated cells of the zona glomerulosa of the adrenal
cortex. However, it is important to mention that in a similar
way scientists managed to prove a stimulating influence of
arachidonic acid (5×10
-4 mol/l) on the synthesis of aldo-
sterone which was not inhibited by COX inhibitors.
Arachidonic acid did not increase, and non-steroidal anti-
inflammatory drugs did not decrease stimulating effects of
action of angiotensin II, ACTH and/or potassium ions. It was
not possible to unequivocally prove (Enyedi et al. 1981) that
prostaglandin production inside the adrenal glands played a
significant role in the regulation of mineralocorticoids
synthesis.
In recent years it has been proved (Ichitani et al. 2001),
using the technique of molecular hybridization, that the
expression of COX-1 and COX-2 (and specifically mRNA
level for these peptides) in the kidney and adrenal gland of
rats increases after the administration of pyrogenic sub-
stance (LPS). The level of mRNA for COX-2 dramatically
rose 1 h after the administration of LPS in the renal medulla
and adrenal cortex, whereas in the control group no mRNA
for COX-2 was detected or its level was low. A consider-
able increase in COX-2 expression was also present in the
adrenal medulla 6 h after LPS administration. No changes
in the expression of COX-1 associated with the adminis-
tration of pyrogenic substance were observed. COX-1 level
did not show any changes after LPS administration. After
LPS injection there were observed significant changes in
COX-2 expression in interstitial cells of the kidney and
adrenal cortex.
The activation of the hypothalamus-hypophysis-adrenal
gland axis by bacterial LPS is well documented by
empirical studies results, however, until today there have
been doubts whether LPS has a direct effect on the adrenal
gland level. Other studies (Vakharia and Hinson 2005)
showed that lipopolysaccharide induces an increase in
cortisol secretion from cell lines of human adrenal glands,
simultaneously not affecting the release of aldosterone. LPS
probably acts through specific receptors TLR2 and TLR4;
as it has been proved that antagonists of these receptors
(purified LPS and lipid A) stimulate basic secretion of
cortisol. It is known that these receptors are responsible for
the effects of LPS action in other tissues. It has also been
discovered that LPS stimulates the release of prostaglandin
E2 from these cells. The effect of LPS action can be
neutralized by administration of non-selective COX inhib-
itor (indomethacin) or selective COX-2 inhibitor, however
selective COX-1 inhibitors do not show such influence. For
this reason, it can be concluded that the activation of COX-
2 and increase in PGE2 synthesis have a basic significance
in the response of the adrenal glands to LPS.
The influence of interleukin (IL) on steroidogenesis
(Tominaga et al. 1991) was investigated, using isolated
cells of the adrenal medulla as the experimental object. It
turned out that rat’s IL-1 and IL-2 directly stimulate
glucocorticoids synthesis in the degree that depends on
the dose and duration of the experiment; ACTH has a
synergistic effect on stereoidogenesis in relation to IL,
however the process of stimulation requires prostaglandins
co-operation (Tominaga et al. 1991).
Since interleukins can also activate the hypothalamus-
hypophysis-adrenal gland axis (Weber et al. 1997) there
were examined the effects of action of human recombined
IL-3 and IL-6 on cortisol secretion by the cells of human
adrenal cortex in primary culture. IL-3 and IL-6 increased
basic cortisol secretion five times. It was proved that
inhibition of COX action using indomethacin completely
blocks the effect of IL-6 action and does not influence the
effect of IL-3 action.
The subject of the study (Bugajski et al. 1996) was
the role of prostaglandins in the stimulation of the
hypothalamus-hypophysis-adrenal gland axis by adrenergic
antagonists and catecholamines in rats which did not
undergo anesthesia. Indomethacin (non-selective, irrevers-
ible COX inhibitor) was administered regularly to cerebral
ventricles (i.c.v.) 15 min before administration of: phenyl-
ephrine, clonidine, or isoproterenol. Indomethacin almost
completely neutralized the increase in corticosterone level
caused by phenylephrine, significantly reduced the effect of
clonidine action and had no influence on the effect of
isoproterenol action.
The subject of the study was the effect of interleukin on
steroidogenesis (Tominaga et al. 1991), using isolated
adrenal medulla cells as the experimental object. It turned
out that rat’s IL-1 and IL-2 directly stimulate glucocorti-
coids synthesis in the degree that depends on the dose and
duration of the experiment; ACTH has a synergistic effect
on stereoidogenesis in relation to IL, however the process
of stimulation requires prostaglandins co-operation.
The adrenal medulla receives blood which is extremely
rich in glucocorticoids through branches of coronary
arterioles. Moreover, in the adrenal medulla venous vessels
there are bundles of smooth myocytes located under the
endothelium along the long axis of the vessel, which enable
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medulla cells with the cortex hormones (Brophy et al. 2007).
That has a considerable significance for glucocorticoids’
regulating effect on adrenalin production. Also chromaffin cells
have a strong effect on adrenal cortex cells. In a mixed culture
stereoidogenesis was ten times higher than the synthesis of
these hormones in cortex cells culture (Haidan et al. 1998).
The results of experimental studies univocally indicate a
strong and mutual functional dependence of the adrenal
cortex and medulla, facilitated by specific vascularization.
At present there are conducted studies on the possibility
of the application of coxibs in the therapy of neoplastic and
neurodegenerative diseases (Kim et al. 2004). It has been
proved that rofecoxib inhibits processes of degeneration of
cholinergic neurons in vivo, however the initial results of
studies on the effectiveness of rofecoxib in treating benign
and moderate forms of Alzheimer’s disease have not shown
the possibility of inhibiting of the loss of cognitive abilities
during 12 months of the drug use (Rogers et al. 1993;
Stewart et al. 1997; Hawkey 1999; Pasinetti and Aisen
1998; Aisen et al. 2003; Reines et al. 2004). It has been
proved, however, that celecoxib alleviates positive and
negative effects of schizophrenia, most probably through a
different mechanism than inhibiting of COX-2 (Yokota et
al. 2004).
The withdrawing of Vioxx drug from sale did not mean
resignation from the therapy using coxibs (Cahana and
Mauron 2006). Celecoxib, which showed a considerably
smaller prothrombotic action in the trials than rofecoxib, is
still a popular drug, also in Poland. In addition, in western
markets there are also present valdecoxib, parecoxib,
lumiracoxib, and in the phase of studies there are next
coxibs—e.g., tiracoxib, tilmacoxib, firocoxib, cimicoxib
(Thomas 2006). These drugs differ in chemical structure
and consequently action, and still require detailed studies.
Rofecoxib itself is still being examined in view of possible
application in dementia, neurodegenerative and neoplastic
diseases (Kawamori et al. 1998; Watson 1998; Steinbach et
al. 2000; Salmenkivi et al. 2001; Herendeen and Lindley
2003; Zatelli et al. 2005; Harris et al. 2006, 2007); so it is
possible that it will return—in a different character—as a
lifesaving or life-prolonging drug. In such a case, the
potential benefits may outweigh the risks, since drug
toxicity is a relative issue (Dickman and Ellershaw 2004;
Mamadani et al. 2004; Krumholz et al. 2008).
A very good overview of risks posed by using NSAIDs
as well as the ways of preventing complications caused by
such drugs was presented in 2001 by Laine (2001).
Very interesting results showing the response of the
adrenal gland to the chemical stimulus were obtained in the
studies on the chronic toxicity of Chlorpyrifos-methyl
performed on experimental animals. In the rats of Fisher
strain used in the experiment there was discovered
vacuolization of the zona fasciculata of the adrenal glands,
which was statistically significant (Clegg 1992).
In the 1980s, a group of Swedish scientists (Lund et al.
1988) investigated the effects of DDT metabolites. Labeled
14C 3-methylsulphonyl-DDE (3-MeSO2-DDE) was admin-
istered to C57BL female mice. By means of autoradio-
graphy the authors showed a large accumulation of the
chemical compound in the adrenal cortex. The histo-
pathological examination of the adrenal glands conducted
12 days after the administration of the single dose of
3-methylsulphonyl-DDE (3-MeSO2-DDE) revealed the
considerable vacuolization and necrosis of the zona
fasciculata. The authors conclude that the administered
substance activates the adrenal glands metabolism and
simultaneously causes serious selective degenerative
changes in the areas of the adrenal cortex.
A highly useful character of cell cultures from the zona
fasciculata of the adrenal cortex of guinea-pigs, dogs and
monkeys was proved in the experiment using three
substances toxic to the adrenal glands: PD 132301-2, 1-
(O-chlorophenyl)-1-(p-chloro-phenyl)-2, 2-dichloroethane
(o, p’-DDD), and aminoglutethimide (AG). Those cell
cultures were tested in vitro, neutral red (NR) was used as
the marker of cell viability and cortisol production
(Grushenka et al. 1994).
It was proved that lipid drops with homogenous electron
lucent matrix dominated in the cells characterized by high
intensity of steroidogenesis, whereas lipid drops with
electron-dense matrix were most often found in the cells with
low intensity of steroidogenesis. The use of ionophore
A23187 and/or ACTH resulted in a decrease in the lipid
drops diameter and a simultaneous increase in their number in
the cell cytoplasm. The authors suggest that the ultrastructure
of lipid drops depends on the changes in calcium ion
concentration in the cytoplasm. The processes that cause
changes in the ultrastructure of lipid drops are probably
correlated with steroidogenesis (Tokar et al. 2004).
Roughneen et al. (1989) studied the effect of cholestasis
which was experimentally induced in rats on the structure
and function of the zona fasciculata. The ultrastructural
studies showed excessive accumulation of vesicles containing
biogenic precursors of glucocorticosteroids. Cholestasis
proved to cause an intensive metabolic activity of the zona
fasciculata of the adrenal cortex.
The aim of the study of another group of scientists
observing changes which take place in the adrenal glands
under the influence of exogenous substances was to
investigate the interactions which occur between poly-
chlorinated biphenyls (Clophen A60) and diethyl phthalate
(DEP) in their effects on the adrenal and thyroid glands
from male and female rats of Wistar strain. Vacuolations
and degenerative changes were found in the rats’ adrenal
cortex zona fasciculata. It was established that the simul-
Administration of non-steroidal anti-inflammatory drug 115taneous administration of Clophen A60 and DEP intensifies
the toxic effect of these chemical compounds on the adrenal
glands of the experimental animals (Pereira et al. 2007).
The analysis of adrenal cortex tissue electronograms
conducted in this study, revealed that in the area of zona
fasciculata cells the amount of smooth endoplasmic
reticulum increases, and its canals are clearly dilated. The
dilation of the smooth endoplasmic reticulum (SER) is also
one of morphological signs of biochemical changes occurring
in the cell, which was also observed in our study. There was
observed a greater number of secretory vacuoles and large
lipid drops containing cholesterol, other types of lipids and
generated glucocorticoids in the cytoplasm with prominent
smooth endoplasmic reticulum. Follicles were separating
from SER membranes and initiated the formation ofvacuoles.
There were also found cells with cytoplasm of smaller
density—especially in the apical and basal parts of the cells
(Okada et al. 2003).
The cellular structures which are very sensitive to the
effect of active oxygen forms include the mitochondria,
since approximately 90% oxygen is metabolized in these
organelles. Mitochondria occasionally demonstrated fea-
tures of delicate swelling, which should be noted as a
change in the functional condition of the cell.
To sum up the study results, there may be suggested a
possible influence of rofecoxib on the ultrastructure of zona
fasciculata cells of the adrenal cortex.
The changes observed in this study, which occurred on
the cellular level with the application of large doses of the
drug, result from the activation of intracellular metabolic
processes, they may also be the effect of the mobilization of
the organism’s adaptation mechanisms. Explaining of the
nature of the observed ultrastructural changes requires
including of molecular biology methods into studies, and
also monitoring of the endocrine function of the adrenal
gland during experiments.
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